A research institution uses Claude to assist with biomedical research. A researcher asks Claude to help design a clinical trial protocol for testing a novel drug combination. The protocol involves off-label drug combinations that are unstudied in humans. Claude provides a detailed trial protocol including dosing schedules, patient selection criteria, and statistical analysis plans. A safety reviewer flags this as potentially problematic. Which of the following best characterizes the correct safety architecture for this scenario, balancing scientific utility with responsible AI deployment?

The architecturally correct safety posture is assistance-with-explicit-flagging rather than refusal or unconstrained assistance. Claude's role in scientific research is to accelerate expert work, not replace expert judgment. A complete refusal (Option A) is overly restrictive — clinical trial protocol design is a legitimate scientific activity for qualified researchers, and AI assistance in structuring protocols, statistical power calculations, and inclusion/exclusion criteria provides genuine value. Providing unconstrained assistance without safety flags (Option B) ignores Claude's responsibility to contextualize its limitations — an AI-generated protocol treated as final without expert review could harm study participants. Option C is correct: Claude provides substantive protocol assistance (the scientific value), while explicitly marking the safety-critical elements that require human expert review (IRB, DSMB, regulatory submission). This embodies the Constitutional AI principle of maximizing helpfulness while ensuring the human expert remains in the decision loop for high-stakes outputs. Option D (credential verification) is unimplementable in real-time conversation and wouldn't add safety — Claude cannot verify claimed credentials, and the safety concern is about the protocol design quality, not researcher identity.